The antiretroviral drug Fuzeon, also known as enfuvirtide and T-20, was licensed by the US Food and Drug Administration (FDA) on 15 March 2003. Fuzeon was the first of a new class of anti-AIDS drugs, called fusion inhibitors, to gain such a license. Unlike all previously approved antiretrovirals, Fuzeon is injected rather than swallowed.